Penumbra (PEN) Q3 Earnings and Revenues Beat Estimates

Core Insights - Penumbra reported quarterly earnings of $0.97 per share, exceeding the Zacks Consensus Estimate of $0.90 per share, and showing an increase from $0.85 per share a year ago, resulting in an earnings surprise of +7.78% [1] - The company achieved revenues of $354.69 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.12% and up from $301.04 million year-over-year [2] - Penumbra has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Company Performance - The stock has underperformed the market, losing about 1% since the beginning of the year, while the S&P 500 gained 15.1% [3] - The current consensus EPS estimate for the upcoming quarter is $1.10 on revenues of $361.16 million, and for the current fiscal year, it is $3.68 on revenues of $1.37 billion [7] - The estimate revisions trend for Penumbra was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Penumbra belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]